Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases

Inclusion Criteria: * At least 18 years of age at screening * Ability to understand the purposes and risks of the study and has signed a written informed consent document approved by the site-specific IRB * Proven and documented LM evidenced by positive CSF cytology or CSF circulating tumor cells, from any primary solid tumor * Patients may have received prior chemotherapy regimens and prior radiation (there is no limit) * Karnofsky performance status of 60 to 100 * Acceptable liver function: * Bilirubin ≤ 1.5 times upper limit of normal * AST (SGOT) and ALT (SGPT) ≤ 3.0 times upper limit of normal for subjects with normal liver * AST (SGOT) and ALT (SGPT) ≤ 5.0 times upper limit of normal for subjects with liver metastasis * Subjects with a creatinine clearance greater than or equal to 60 mL/min (using the Cockcroft-Gault Equation) for males and females. * Acceptable hematologic status (without hematologic support): * ANC ≥ 1000 cells μL * Platelet count ≥ 75,000/μL * Hemoglobin ≥ 9.0 g/dL * PT/INR and PTT ≤1.5 x ULN, unless treated with anticoagulants * All women of childbearing potential must have a negative serum pregnancy test at screening. Male and female subjects must agree to use effective means of contraception (for example, surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) with their partner from entry into the study through 6 months after the last dose. Exclu…